Soft tissue sarcomas are among rare diseases, the incidence of which in Europe is between 4-5/10,000 inhabitants. In recent decades of research on these tumors, it has become clear that some of them are defined, together with morphological criteria, by specific chromosomal changes, especially translocations.
Despite the intensive development of targeted therapy based on specific molecular features and knowledge of tumor biology in the field of solid tumors and hematological malignancies, there are only a few subtypes of soft tissue sarcomas where treatment is guided by histological type or the presence of specific molecular biological characteristics.